Rhode Island Chronicle

Epstein Barr Virus Market to Register Immense Growth During the Forecast Period (2022-2032) – DelveInsight | Allovir, Viracta, RAPT Therapeutics, Atara Biotherapeutics, Tessa Therapeutics

 Breaking News
  • No posts were found

Epstein Barr Virus Market to Register Immense Growth During the Forecast Period (2022-2032) – DelveInsight | Allovir, Viracta, RAPT Therapeutics, Atara Biotherapeutics, Tessa Therapeutics

June 07
06:04 2023
Epstein Barr Virus Market to Register Immense Growth During the Forecast Period (2022-2032) - DelveInsight | Allovir, Viracta, RAPT Therapeutics, Atara Biotherapeutics, Tessa Therapeutics
Delveinsight Business Research LLP
The Epstein–Barr Virus market size in the seven major markets was approximately USD 1.5 billion in 2021, which is anticipated to grow by 2032. As per DelveInsight, the Epstein Barr Virus Market is anticipated to evolve immensely in the coming years owing to the increase in the research and development programs related to Epstein–Barr Virus and the rise in the number of cases of Epstein Barr Virus.

Various companies are working to develop many therapies for the treatment of EBV+Cancers and PTLD. Key players such as Atara Biotherapeutics, Tessa Therapeutics, AlloVir are some of the major players that are going to boost the market dynamics in the coming years. The availability of these therapies holds the potential to change prescription patterns as well as the market scenario.

DelveInsight’s “Epstein Barr Virus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epstein Barr Virus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Epstein Barr Virus drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Epstein Barr Virus treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Epstein Barr Virus Market

Epstein Barr Virus: An Overview

Epstein–Barr virus (EBV), also known as human herpesvirus 4, is a member of the Herpesviridae family and is a ubiquitous pathogen that is persistently harbored by people throughout the world. EBV is the major cause of infectious mononucleosis (IM) and is associated with several malignancies including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and lymphoma after the organ or stem cell transplant.

There are two types of EBV: type I and type II, also known as Types A and B. These two genotypes were distinguished based on the differences in the EBNA-2 gene. Additionally, Epstein–Barr virus Type I and II can further be subtyped into different EBV strains.

Epstein Barr Virus Market Key Facts

  • The total number of Epstein–Barr Virus IM cases in the 7MM countries was more than 1,120,000+ in 2021.

  • As per the estimates, the United States had the highest number of incident cases of Epstein–Barr Virus in 2021 among the 7MM.

  • Among EU4 and the UK, Germany had the highest number of Epstein–Barr Virus cases, with more than 146,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of Epstein–Barr Virus cases, with close to 79,000 cases in 2021.

Epstein Barr Virus Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Epstein Barr Virus pipeline therapies. It also thoroughly assesses the Epstein Barr Virus market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Epstein Barr Virus drugs and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Epstein Barr Virus Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Epstein Barr Virus epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Epstein Barr Virus epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Epstein Barr Virus Epidemiology, Segmented as –

  • Total Incident cases of EBV+ Cancers [2019–2032]

  • Total Incident cases of EBV+ PTLD [2019–2032]

  • Total Incident cases of EBV-associated tumors in the 7MM [2019–2032]

  • Total Diagnosed cases of EBV Infectious Mononucleosis [2019–2032]

Epstein Barr Virus Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Epstein Barr Virus market or expected to be launched during the study period. The analysis covers the Epstein Barr Virus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Epstein Barr Virus drugs based on their sale and market share.

The report also covers the Epstein Barr Virus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Epstein Barr Virus companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Epstein Barr Virus Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/epstein-barr-virus-ebv-market

Epstein Barr Virus Companies Actively Working in the Therapeutics Market Include

  • Viracta Therapeutics

  • Atara Biotherapeutics

  • AlloVir

And Many Others

Emerging and Marketed Epstein Barr Virus Therapies Covered in the Report Include:

  • Tabelecleucel: Atara Biotherapeutics

  • Posoleucel (ALVR105): Allovir

  • TT10: Tessa Therapeutics

  • Nanatinostat: Viracta Therapeutics

  • FLX475: RAPT Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/epstein-barr-virus-ebv-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Epstein Barr Virus Competitive Intelligence Analysis

4. Epstein Barr Virus Market Overview at a Glance

5. Epstein Barr Virus Disease Background and Overview

6. Epstein Barr Virus Patient Journey

7. Epstein Barr Virus Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Epstein Barr Virus Treatment Algorithm, Current Treatment, and Medical Practices

9. Epstein Barr Virus Unmet Needs

10. Key Endpoints of Epstein Barr Virus Treatment

11. Epstein Barr Virus Marketed Therapies

12. Epstein Barr Virus Emerging Drugs and Latest Therapeutic Advances

13. Epstein Barr Virus Seven Major Market Analysis

14. Attribute Analysis

15. Epstein Barr Virus Market Outlook (In US, EU5, and Japan)

16. Epstein Barr Virus Companies Active in the Market

17. Epstein Barr Virus Access and Reimbursement Overview

18. KOL Views on the Epstein Barr Virus Market

19. Epstein Barr Virus Market Drivers

20. Epstein Barr Virus Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/epstein-barr-virus-ebv-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Throat Cancer Market

“Throat Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Throat Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Throat Cancer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories